1.    http://www.ncbi.nlm.nih.gov/pubmed/677146/ 
2.    Atkuri, K.R., et al. “N-Acetylcysteine — a safe antidote for cysteine/glutathione deficiency”. Current Opinion in Pharmacology Vol. 7, No. 4 (2007): 355–359.
3.    http://www.ncbi.nlm.nih.gov/pubmed/16439183
4.    http://www.ncbi.nlm.nih.gov/pubmed/25957927
5.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553161/ 
6.    http://www.ncbi.nlm.nih.gov/pubmed/11673605/ 
7.    http://www.ncbi.nlm.nih.gov/pubmed/12512991
8.    http://www.ncbi.nlm.nih.gov/pubmed/2029805/ 
9.    http://www.ncbi.nlm.nih.gov/pubmed/18004285/ 
10.    http://www.ncbi.nlm.nih.gov/pubmed/11691805  
11.    http://www.ncbi.nlm.nih.gov/pubmed/12603840
12.    http://www.ncbi.nlm.nih.gov/pubmed/20021321
13.    http://www.ncbi.nlm.nih.gov/pubmed/19122532
14.    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044191/ 
15.    http://www.ncbi.nlm.nih.gov/pubmed/17401648/ 
16.    http://www.ncbi.nlm.nih.gov/pubmed/12584726/ 
17.    http://www.ncbi.nlm.nih.gov/pubmed/12512991
18.    http://www.ncbi.nlm.nih.gov/pubmed/24752591  
19.    http://www.ncbi.nlm.nih.gov/pubmed/25004186
20.    Andreazza, A.C., et al. “Oxidative stress markers in bipolar disorder: a meta-analysis”. Journal of Affective Disorders Vol. 111, No. 2–3 (2008): 135–144. 
21.    Kim, H.K., et al. “Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia”. Journal of Psychiatry & Neuroscience Vol. 39, No. 1 (2014): 130155.
22.    Wang, J.F., et al. “Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia”. Bipolar Disorders Vol. 11, No. 5 (2009): 523–529.
23.    Gawryluk, J.W., et al. “Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders”. The International Journal of Neuropsychopharmacology Vol. 14, No. 1 (2011): 123–130.
24.    Holmay, M.J., et al. “N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases”. Clinical Neuropharmacology Vol. 36, No. 4 (2013): 103–106.
25.    Gawryluk, J.W., et al. “Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders”. The International Journal of Neuropsychopharmacology Vol. 14, No. 1 (2011): 123–130
26.    Gigante, A.D., et al. “Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis”. Bipolar Disorders Vol. 14, No. 5 (2012): 478–487.
27.    Berk, M., et al. “The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial”. Journal of Affective Disorders Vol. 135, No. 1–3 (2011): 389–394.
28.    http://www.ncbi.nlm.nih.gov/pubmed/18534556
29.    Magalhães, P.V., et al. “N-Acetylcysteine for major depressive episodes in bipolar disorder”. Revista Brasileira de Psiquiatria Vol. 33, No. 4 (2011): 374–378.
30.    Magalhães P.V., et al. “N-Acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of Affective Disorders Vol. 129, No. 1–3 (2011): 317–320.
31.    Magalhães, P.V., et al. “A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania”. The Australian and New Zealand Journal of Psychiatry Vol. 47, No. 6 (2013): 564–568.
32.     http://www.ncbi.nlm.nih.gov/pubmed/18539338/ 
33.    http://www.ncbi.nlm.nih.gov/pubmed/19568477/ 
34.    http://www.ncbi.nlm.nih.gov/pubmed/16449100/ 
35.    http://www.ncbi.nlm.nih.gov/pubmed/17606664/ 
36.    http://www.ncbi.nlm.nih.gov/pubmed/17113207/ 
37.    http://www.ncbi.nlm.nih.gov/pubmed/19103434
38.    http://www.ncbi.nlm.nih.gov/pubmed/17445781
39.    http://www.ncbi.nlm.nih.gov/pubmed/12207144
40.    http://www.ncbi.nlm.nih.gov/pubmed/19272303
41.    http://www.ncbi.nlm.nih.gov/pubmed/16682105
42.    http://www.ncbi.nlm.nih.gov/pubmed/18957313
43.    http://www.ncbi.nlm.nih.gov/pubmed/18006203
44.    http://link.springer.com/article/10.1007/s00213-005-0246-6
45.    http://www.ncbi.nlm.nih.gov/pubmed/19468281/ 
46.    http://www.ncbi.nlm.nih.gov/pubmed/23826003
47.    http://www.ncbi.nlm.nih.gov/pubmed/22342106
48.    http://www.ncbi.nlm.nih.gov/pubmed/23886027
49.    http://www.ncbi.nlm.nih.gov/pubmed/21519954
50.    http://www.ncbi.nlm.nih.gov/pubmed/22225920
51.    http://www.ncbi.nlm.nih.gov/pubmed/22127832
52.    http://www.ncbi.nlm.nih.gov/pubmed/16081262
53.    http://www.ncbi.nlm.nih.gov/pubmed/22528835
54.    http://www.ncbi.nlm.nih.gov/pubmed/21484198
55.    http://www.ncbi.nlm.nih.gov/pubmed/22051046
56.    http://www.ncbi.nlm.nih.gov/pubmed/21967199
57.    http://www.ncbi.nlm.nih.gov/pubmed/22653211
58.    http://www.ncbi.nlm.nih.gov/pubmed/17502791
59.    http://www.ncbi.nlm.nih.gov/pubmed/22342106
60.    http://www.ncbi.nlm.nih.gov/pubmed/22579303
61.    http://www.ncbi.nlm.nih.gov/pubmed/18538422/ 
62.    http://www.ncbi.nlm.nih.gov/pubmed/18436195/ 
63.    http://www.ncbi.nlm.nih.gov/pubmed/20868637/ 
64.    http://www.ncbi.nlm.nih.gov/pubmed/19735056/ 
65.    http://www.ncbi.nlm.nih.gov/pubmed/19103434/ 
66.    http://www.ncbi.nlm.nih.gov/pubmed/18440072
67.    http://www.ncbi.nlm.nih.gov/pubmed/18996163
68.    http://www.ncbi.nlm.nih.gov/pubmed/18225476
69.    Carmeli, C., et al. “Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial”. PLoS One Vol. 7, No. 2 (2012): e29341.
70.    https://www.researchgate.net/publication/258347895_N-Acetylcysteine_as_an_Adjunct_to_Risperidone_for_Treatment_of_Negative_Symptoms_in_Patients_With_Chronic_Schizophrenia_A_Randomized_Double-Blind_Placebo-Controlled_Study
71.    http://www.ncbi.nlm.nih.gov/pubmed/19689277
72.    http://www.ncbi.nlm.nih.gov/pubmed/19576938
73.    http://www.ncbi.nlm.nih.gov/pubmed/19788631
74.    http://www.ncbi.nlm.nih.gov/pubmed/18205981